Richard Wolf and Photocure are developing a new flexible PDD-cystoscope
(Knittlingen, 02. August 2024). Following a period of in-depth preparation, in July Business Development announced that Richard Wolf and Photocure, a company focused on the management of bladder cancer, had successfully established a strategic partnership with the aim of developing a new flexible blue light-enabled cystoscope for photodynamic diagnostics (PDD).
This equipment is designed to cater to the large and, as yet, unfulfilled need for screening, diagnosis and surveillance cystoscopies on outpatients with bladder cancer. The two companies have concluded an agreement for developing and marketing a reusable, flexible, next-generation cystoscope based on PDD technology from Richard Wolf. The strategic partnership between Richard Wolf and Photocure is built on a long-standing relationship between the two companies, which incorporates co-promotion, health awareness, information, market development, and clinical research.
Plans for the future: When the US drug authorities decide to reclassify blue-light medical devices in the USA, Richard Wolf will aim to obtain clearance in the USA and, at the same time, will register the CE marking in Europe. We will then work with Photocure to advertise the new flexible bluelight-enabled system worldwide. The plan will also be to use existing sales organizations as channels for publicizing the new, reusable flexible system in North America and Europe.
About Richard Wolf:
Richard Wolf GmbH is a medium-sized medical technology company with over 1,800 employees, along with eighteen subsidiaries and 130 foreign agencies worldwide. The company develops, produces, and distributes numerous products for endoscopy and extracorporeal shock wave treatment in human medicine. Integrated operating room systems round out the product range.
About Photcure:
The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com
